JP2016530291A5 - - Google Patents

Download PDF

Info

Publication number
JP2016530291A5
JP2016530291A5 JP2016539645A JP2016539645A JP2016530291A5 JP 2016530291 A5 JP2016530291 A5 JP 2016530291A5 JP 2016539645 A JP2016539645 A JP 2016539645A JP 2016539645 A JP2016539645 A JP 2016539645A JP 2016530291 A5 JP2016530291 A5 JP 2016530291A5
Authority
JP
Japan
Prior art keywords
metadoxine
composition
sustained release
disorder
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016539645A
Other languages
Japanese (ja)
Other versions
JP2016530291A (en
Filing date
Publication date
Priority claimed from US14/038,258 external-priority patent/US20150073023A1/en
Application filed filed Critical
Priority claimed from PCT/IB2014/002398 external-priority patent/WO2015033224A2/en
Publication of JP2016530291A publication Critical patent/JP2016530291A/en
Publication of JP2016530291A5 publication Critical patent/JP2016530291A5/ja
Pending legal-status Critical Current

Links

Claims (9)

脆弱Ｘ症候群または関連障害の症状の処置または緩和のための、メタドキシンを含んでなる組成物。 A composition comprising metadoxine for the treatment or alleviation of symptoms of fragile X syndrome or related disorders . １００〜３０００ｍｇの間の総一日用量のメタドキシンを投与することを含んでなる、請求項１に記載の組成物。 2. The composition of claim 1 comprising administering a total daily dose of metadoxine between 100 and 3000 mg. 前記メタドキシンが毎日、１日おきに、または毎週投与される、請求項１に記載の組成物。 The composition of claim 1, wherein the metadoxine is administered daily, every other day, or weekly. 前記メタドキシンが１日当たり１、２、または３種類の剤形で投与される、請求項１に記載の組成物。 The composition of claim 1, wherein the metadoxine is administered in one, two, or three dosage forms per day. 前記メタドキシンが持続放出経口剤形で投与され、前記メタドキシンが徐放形態と即時放出形態の組合せとして処方される、請求項１に記載の組成物。 2. The composition of claim 1, wherein the metadoxine is administered in a sustained release oral dosage form and the metadoxine is formulated as a combination of a sustained release form and an immediate release form. （ａ）徐放形態が少なくとも８時間の前記メタドキシンの持続放出を提供し、かつ、
（ｂ）徐放メタドキシンと即時放出メタドキシンの相対比が約６０：４０〜８０：２０の間である、
請求項５に記載の組成物。 (A) the sustained release form provides a sustained release of said metadoxine for at least 8 hours; and
(B) the relative ratio of sustained release metadoxine and immediate release metadoxine is between about 60:40 and 80:20;
The composition according to claim 5. 前記徐放メタドキシンと前記即時放出メタドキシンの相対比が約６５：３５である、請求項６に記載の組成物。 7. The composition of claim 6, wherein the relative ratio of the sustained release metadoxine and the immediate release metadoxine is about 65:35. 前記症状が学習障害または社会的行動障害である、請求項１に記載の組成物。 The composition of claim 1, wherein the symptom is a learning disorder or a social behavior disorder. 前記関連障害が自閉症スペクトラム障害である、請求項１に記載の組成物。 The composition of claim 1, wherein the related disorder is an autism spectrum disorder.
JP2016539645A 2013-09-09 2014-09-09 Method for treating fragile X syndrome and related disorders Pending JP2016530291A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361875384P 2013-09-09 2013-09-09
US61/875,384 2013-09-09
US14/038,258 2013-09-26
US14/038,258 US20150073023A1 (en) 2013-09-09 2013-09-26 Method Of Treating Fragile X Syndrome And Related Disorders
US201461991351P 2014-05-09 2014-05-09
US61/991,351 2014-05-09
PCT/IB2014/002398 WO2015033224A2 (en) 2013-09-09 2014-09-09 Methods of treating fragile x syndrome and related disorders

Publications (2)

Publication Number Publication Date
JP2016530291A JP2016530291A (en) 2016-09-29
JP2016530291A5 true JP2016530291A5 (en) 2017-10-19

Family

ID=52629036

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016540930A Pending JP2016530536A (en) 2013-09-09 2014-09-09 Of determining response to therapy
JP2016539645A Pending JP2016530291A (en) 2013-09-09 2014-09-09 Method for treating fragile X syndrome and related disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016540930A Pending JP2016530536A (en) 2013-09-09 2014-09-09 Of determining response to therapy

Country Status (12)

Country Link
EP (2) EP3044589A1 (en)
JP (2) JP2016530536A (en)
KR (2) KR20160078956A (en)
CN (2) CN105917225A (en)
AU (2) AU2014315026A1 (en)
CA (2) CA2922901A1 (en)
EA (2) EA201690559A1 (en)
IL (2) IL244343A0 (en)
MX (2) MX2016003002A (en)
SG (2) SG11201601830PA (en)
TW (2) TW201605443A (en)
WO (2) WO2015035402A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3239161A1 (en) * 2013-07-31 2017-11-01 UDC Ireland Limited Luminescent diazabenzimidazole carbene metal complexes
US20150073023A1 (en) 2013-09-09 2015-03-12 Alcobra Ltd. Method Of Treating Fragile X Syndrome And Related Disorders
CN108538365A (en) * 2017-03-24 2018-09-14 华东师范大学 A kind of self-closing disease sociability assessment system based on data analysis technique
JP2021524836A (en) * 2018-04-13 2021-09-16 ヒールクス リミテッドＨｅａｌｘ Ｌｉｍｉｔｅｄ Treatment of Fragile X Syndrome
KR20190121569A (en) * 2018-04-18 2019-10-28 건국대학교 글로컬산학협력단 Pharmaceutical Composition for Improving Fragile X Syndrome Comprising Agmatine or its derivatives
EP3813816B1 (en) * 2018-06-07 2023-06-07 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid in the treatment of fragile x syndrome or fragile x-associated tremor/ataxia syndrome
JP2023523119A (en) * 2020-01-08 2023-06-02 ニューロヴェンティ カンパニー リミテッド Composition for treating fragile X syndrome or related developmental disorders containing a lisuride compound as an active ingredient
EP4101448A4 (en) * 2020-02-07 2024-04-24 Neuroventi Composition comprising rilmenidine compound as active ingredient for treatment of fragile x syndrome or related developmental disability

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1131856B (en) 1980-06-30 1986-06-25 Baldacci Lab Spa PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALCOHOLIC INTOXICATIONS
WO2002043507A2 (en) * 2000-11-30 2002-06-06 The Health Research Institute Nutrient supplements and methods for treating autism and for preventing the onset of autism
IL187159A0 (en) 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication
NZ597319A (en) * 2009-06-25 2014-06-27 Alcobra Ltd A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition

Similar Documents

Publication Publication Date Title
JP2016530291A5 (en)
HRP20210819T1 (en) Fenfluramine for use in the treatment of dravet syndrome
JP2018193377A5 (en)
JP2012193216A5 (en)
JP2010248252A5 (en)
MY181159A (en) Sublingual and buccal film compositions
JP2015057451A5 (en)
JP2014111603A5 (en)
JP2015515475A5 (en)
JP2016147915A5 (en)
UA109991C2 (en) CARBAMATE COMPOUNDS, THEIR PREPARATION AND APPLICATION
JP2015517488A5 (en)
JP2013505205A5 (en)
JP2013231087A5 (en)
RU2017116740A (en) COMBINATIONS FOR THE TREATMENT OF MULTIPLE SCLEROSIS
JP2015525757A5 (en)
MX340985B (en) N-heteroaryl compounds.
AR091351A1 (en) BROMOCRIPTINE FORMULATIONS, METHOD FOR IMPROVING GLUCEMIC CONTROL AND METHOD FOR MANUFACTURING
JP2014507474A5 (en)
MX340188B (en) Manufacturing of active-free granules and tablets comprising the same.
CO6612185A2 (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorders
JP2013541583A5 (en)
BR112014014795A2 (en) immediate release multi-unit pellet system
JP2014507475A5 (en)
WO2015009731A3 (en) Azacyclic constrained analogs of fty720